How to Address Increasing Neurofilament Light Chain Levels
Opinion
Video
This program is supported by Novartis Pharmaceuticals Corporation. Content is independently developed by CMSC.
Tanuja Chitnis, MD, shares possible course of action if NFL levels begin to rise during treatment.
EP: 1.The Value of Biomarker in Multiple Sclerosis
EP: 2.Evolving Methods of Multiple Sclerosis Diagnosis
EP: 3.Assays to Detect Neurofilament Light
EP: 4.Challenges and Opportunity With MRI
EP: 5.Neurofilament Light Chain and Acute Gadolinium Enhancing Lesions
EP: 6.Exploring Potential Applications of Neurofilament Light Chain in MS Prognosis and Care
EP: 7.Practical Considerations for the Use of Neurofilament Light Chain and MRI
Now Viewing
EP: 8.How to Address Increasing Neurofilament Light Chain Levels
EP: 9.Weighing Treatment Decisions Based on Neurofilament Light Chain Levels
EP: 10.Monitoring Patients After a Change in Treatment Regimen
EP: 11.Assessing Lesion Types With MS Biomarkers
EP: 12.Neurofilament Light Chain and MS Prognosis, Treatment Effect, and Anticipation of Disease
EP: 13.The CLIMB Study
EP: 14.Reimbursement for MRI
EP: 15.Understanding the Underlying Progression of Multiple Sclerosis
EP: 16.Biomarkers, Patient Communication, and the Future of Care
EP: 17.Question and Answer about Neurofilament Light Chain and Other MS Biomarkers
Tanuja Chitnis, MD, expresses a preference for conducting an MRI and personally examining the patient to gather a comprehensive understanding of the situation. She emphasizes the need to identify potential asymptomatic new changes on the neurological exam. Additionally, she acknowledges that the level of comfort and confidence in interpreting NFL changes may evolve in the future.
Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.
This program is supported by Novartis Pharmaceuticals Corporation. Content is independently developed by CMSC.
Related Videos
Related Content
